Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > This is just wonderful news from the vaccine side---
View:
Post by Impalaman on Feb 07, 2022 10:42am

This is just wonderful news from the vaccine side---

Alot of us did not expect---maybe hoped for----and now the bladder cancer results just around the corner---HOW WONDERFUL------HOLY__MACARONI----Too the MOON ALICE.
Comment by enriquesuave on Feb 07, 2022 10:46am
A whole vaccine platform in the making. Awesome.  "Arkady Mandel, interim CEO and Chief Scientific Officer at Theralase, said the research also demonstrates that the Theralase platform is "extremely versatile", with an ability to be applicable to a wide range of enveloped viruses."
Comment by Gooseybear on Feb 07, 2022 10:53am
At long last, great press release.
Comment by Oden6570 on Feb 07, 2022 10:56am
And as a result our value has substantially increased IMHO .
Comment by Eoganacht on Feb 07, 2022 2:23pm
Awesome indeed! There are 7 human corona viruses. The 4 common ones - HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 are responsible for 15-30% of the cases of the common cold. The other 3 - MERS, SARS and COVID-19 are more serious (as we all know). TLD1433 has also proven effective against the H1N1 and ZIKA flu viruses. The potential of a possible Theralase anti-viral vaccine platform is ...more  
Comment by Legit62 on Feb 07, 2022 2:40pm
Great post, thats exactly what i was thinking, basically we just need some attention and the rest will take care of itself, companies with a great product, or service, or treatment always do well, this is a big  reason i invested in this game changing company. and hopefully their cancer treatment helps or cures thousands of people suffering this deadly disease, cancer
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250